What Mineralys Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 2 |
| Sells | 6 | 80 |
| Total trades | 13 | 160 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 147,245 | 1,451,247 |
| Disposed | 199,365 | 2,324,469 |
| Net activity | −52,120 | −873,222 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Peterson Kristine | Director | Oct 19 | Grant / award · A | +12,400 | — | — | 12,400 |
| Coats Lonnel | Director | Oct 19 | Grant / award · A | +12,400 | — | — | 12,400 |
| Congleton Jon | Chief Executive Officer | Sep 30 | Open-market sale · S | −75,000 | $25.46 | −$1.91M | 528,621 |
| Slingsby Brian Taylor | Director | Sep 22 | Open-market sale · S | −104,320 | $28.81 | −$3.01M | 7,805,718 |
| Warren Eric | Chief Commercial Officer | Sep 21 | Open-market sale · S | −7,438 | $28.12 | −$209K | 38,400 |
| Warren Eric | Chief Commercial Officer | Sep 21 | Exercise / conversion · M | +7,438 | $13.24 | +$98.5K | 45,838 |
| Karydas Daphne | Director | Sep 15 | Open-market sale · S | −3,000 | $28.58 | −$85.7K | 6,200 |
| Karydas Daphne | Director | Sep 15 | Exercise / conversion · M | +3,000 | $12.02 | +$36.1K | 9,200 |
| Warren Eric | Chief Commercial Officer | Aug 21 | Open-market sale · S | −7,437 | $25.98 | −$193K | 38,400 |
| Warren Eric | Chief Commercial Officer | Aug 21 | Exercise / conversion · M | +7,437 | $13.24 | +$98.5K | 45,837 |
| Rodman David Malcom | Chief Medical Officer | Aug 10 | Open-market sale · S | −2,170 | $27.09 | −$58.8K | 51,384 |
| Rodman David Malcom | Chief Medical Officer | Aug 10 | Exercise / conversion · M | +2,170 | $16.00 | +$34.7K | 53,554 |
| Ferguson James J. Iii | Chief Medical Officer | Aug 10 | Grant / award · A | +102,400 | — | — | 102,400 |
| Warren Eric | Chief Commercial Officer | Jul 21 | Open-market sale · S | −7,438 | $26.87 | −$200K | 38,400 |
| Warren Eric | Chief Commercial Officer | Jul 21 | Exercise / conversion · M | +7,438 | $13.24 | +$98.5K | 45,838 |
| Rodman David Malcom | Chief Medical Officer | Jul 17 | Open-market sale · S | −416 | $26.53 | −$11K | 51,384 |
| Rodman David Malcom | Chief Medical Officer | Jul 17 | Exercise / conversion · M | +416 | $15.44 | +$6.42K | 51,800 |
| Rodman David Malcom | Chief Medical Officer | Jul 15 | Open-market sale · S | −6,349 | $26.61 | −$169K | 51,384 |
| Rodman David Malcom | Chief Medical Officer | Jul 13 | Open-market sale · S | −14,058 | $27.58 | −$388K | 57,733 |
| Rodman David Malcom | Chief Medical Officer | Jul 13 | Exercise / conversion · M | +6,349 | $1.08 | +$6.86K | 71,791 |
Loading...
